Biocase Brasil
↗Itajaí, Brazil
Biocase Brasil is a Brazilian biopharmaceutical company focused on developing medicinal therapies from natural sources, specifically cannabis and psychedelics. The company operates at the intersection of biotechnology and healthcare, aiming to provide solutions for pathologies that are difficult to control through traditional medicine.
Biocase has shifted its strategic focus from cannabis to psychedelic research, with a primary emphasis on psilocybin-based treatments for conditions such as major depression. The company utilizes partnerships with academic and public laboratories, such as CERTBIO, to conduct pre-clinical research and development, aiming to advance these therapies into clinical trials within the Brazilian regulatory framework overseen by ANVISA.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$3M
Investors:Family Office
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Psychedelics (Psilocybin), Cannabinoids
Active Trials:1
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CERTBIO (Laboratório de Avaliação e Desenvolvimento de Biomateriais do Nordeste) - Research and development partnership for psychedelics.
COMPETITION
Position:Emerging
Competitors:GW Pharmaceuticals, Other Brazilian medical cannabis/psychedelic startups
LEADERSHIP
Key Executives:
Sergio Fadul - CEO
César Câmara - CCO
LINKS
Website:biocasebrasil.com.br
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Biocase Brasil and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biocase Brasil. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.